Incanthera (AQSE:INC) Gross-Profit-to-Asset % : 0.00% (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Incanthera Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Incanthera's annualized Gross Profit for the quarter that ended in Sep. 2023 was £0.00 Mil. Incanthera's average Total Assets over the quarter that ended in Sep. 2023 was £0.18 Mil. Therefore, Incanthera's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 0.00%.

Incanthera Gross-Profit-to-Asset % Historical Data

The historical data trend for Incanthera's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Gross-Profit-to-Asset % Chart

Incanthera Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Gross-Profit-to-Asset %

Incanthera Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Incanthera's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Incanthera's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incanthera's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incanthera's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Incanthera's Gross-Profit-to-Asset % falls into.

Incanthera Gross-Profit-to-Asset % Calculation

Incanthera's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2023 )	/	( (Total Assets (A: Mar. 2022 )	+	Total Assets (A: Mar. 2023 ))	/ count )
	=	0	/	( (1.028	+	0.197)	/ 2 )
	=	0	/	0.6125
	=	0.00 %

Incanthera's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	0	/	( (0.197	+	0.161)	/ 2 )
	=	0	/	0.179
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Incanthera Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Incanthera's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Incanthera (AQSE:INC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

76 King Street, Manchester, GBR, M2 4NH

Website

http://www.incanthera.com

Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines